Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 5:30PM Today MINNEAPOLIS , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional
View HTML
Toggle Summary Predictive Oncology to Report Second Quarter 2019 Financial Results and Provide Company Update on Monday, August 19, 2019
Conference Call to be held August 19, 2019, at 4:30pm Eastern Time MINNEAPOLIS , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the
View HTML
Toggle Summary Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems in India
MINNEAPOLIS , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals.
View HTML
Toggle Summary Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models
Three Most Recent Pittsburgh-Based Development Partnerships Demonstrate Value and Recognition for Helomics’ AI-Driven, Patient Derived “Multi-Omic” Discovery Platform MINNEAPOLIS , July 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a
View HTML
Toggle Summary Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer
PITTSBURGH , July 18, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products
View HTML
Toggle Summary Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment
MINNEAPOLIS, Minn ., June 26, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement
View HTML
Toggle Summary Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Officer of Helomics
MINNEAPOLIS , June 12, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Amelia Warner , Pharm.D., RPh, as the
View HTML
Toggle Summary Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc.
Nasdaq ticker expected to change to POAI Effective Thursday, June 13, 2019 MINNEAPOLIS , June 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery,
View HTML
Toggle Summary Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant
MINNEAPOLIS , May 21, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. , (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that its Helomics division has been selected as the
View HTML
Toggle Summary Precision Therapeutics Gains Extension for Nasdaq Compliance
MINNEAPOLIS , May 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that Nasdaq has determined that the Company is eligible for a
View HTML